WT 1 expression in nevi and melanomas: A marker of melanocytic invasion into the dermis

Journal of Cutaneous Pathology

Volumn 37, Issue 5, 2010, Pages 542-548

  Garrido Ruiz, M C ^a   Rodriguez Pinilla, S M ^b   Perez Gomez B ^c   Rodriguez Peralto, J L ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; WT1 PROTEIN;

ARTICLE; CANCER INVASION; DERMIS; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; MORTALITY; NEVUS; PATHOLOGY; SKIN TUMOR; TISSUE MICROARRAY;

DERMIS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM INVASIVENESS; NEVUS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 77949797816     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2009.01379.x     Document Type: Article

References (45)

1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990 60 : 509.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990 343 : 774.
3. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990 61 : 1257.
4. Davies JA, Ladomery M, Hohenstein P, et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the WT1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 2004 13 : 235.
5. Little MH, Prosser J, Condie A, Smith PJ, van Heyningen V, Hastie ND. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci U.S.A. 1992 89 : 4791.
6. Tadokoro K, Fujii H, Ohshima A, et al. Intragenic homozygous deletion of the WT1 gene in Wilms' tumor. Oncogene 1992 7 : 1215.
7. Scharnhorst V, Van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001 273 : 141.
8. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991 67 : 437.
9. Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991 353 : 431.
10. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990 346 : 194.
11. Menke A, McInnes L, Hastie ND, Schedl A. The Wilms' tumor suppressor WT1: approaches to gene function. Kidney Int 1998 53 : 1512.
12. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996 87 : 2878.
13. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996 88 : 2267.
14. Oji Y, Yamamoto H, Nomura M, et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003 94 : 712.
15. Silberstein GB, van Horn K, Strickland P, Roberts CT Jr., Daniel CW. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U.S.A. 1997 94 : 8132.
16. Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002 100 : 297.
17. Amini Nik S, Hohenstein P, Jadidizadeh A, et al. Up-regulation of Wilms' tumor gene 1 (WT1) in desmoid tumours. Int J Cancer 2005 114 : 202.
18. Oji Y, Suzuki T, Nakano Y, et al. Overexpression of the Wilms' tumor gene 1 in primary astrocytic tumors. Cancer Sci 2004 95 : 822.
19. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999 90 : 194.
20. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002 8 : 1167.
21. Perry BN, Cohen C, Govindarajan B, Cotsonis G, Arbiser JL. Wilms' tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol 2006 142 : 1031.
22. Wilsher M, Cheerala B. WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 2007 51 : 605.
23. Queirolo P, Acquati M, Kirkwood JM, Eggermont AM, Rocca A, Testori A. Update: current management issues in malignant melanoma. Melanoma Res 2005 15 : 319.
24. Kononen J, Bundendorf L, Kallioniemi A, et al. Tissue microarrays for high throughput molecular profiling of tumor specimens. Nat Med 1998 4 : 844.
25. Misago N. The relationship between melanocytes and peripheral nerve sheath cells (Part 1): melanocytic nevus (excluding so-called blue-nevus") with peripheral nerve sheath differentiation. Am J Dermatopathol 2000 22 : 217.
26. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995 146 : 344.
27. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000 24 : 598.
28. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear vs cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001 125 : 1316.
29. Carpentieri DF, Nichols K, Chou PM, Matthews M, Pawel B, Huff D. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 2002 15 : 1080.
30. Sebire NJ, Gibson S, Rampling D, Williams S, Malone M, Ramsay AD. Immunohistochemical findings in embryonal small round cell tumors with molecular diagnostic confirmation. Appl Immunohistochem Mol Morphol 2005 13 : 1.
31. Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004 12 : 122.
32. Caricasole A, Duarte A, Larsson SH, et al. RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci U.S.A. 1996 93 : 7562.
33. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006 19 : 804.
34. Drakos E, Rassidakis GZ, Lai R, Jones D, Medeiros LJ. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 2005 13 : 132.
35. Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR. Regulation of WT1 by phosphorilation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J 1996 15 : 5606.
36. Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 2004 13 : 463.
37. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998 12 : 3217.
38. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for WT1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 1999 126 : 1845.
39. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, gene WT1. Hum Mol Genet 2006 15 : R196.
40. Alonso SR, Ortiz P, Pollán, Pérez-Gomez B, et al. Progression in cutaneous malignant melanomais associated wth distinct expression profiles. A Tissue microarray based study. Am J Pathol 2004 164 : 193.
41. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996 12 : 1005.
42. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000 96 : 1480.
43. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms tumor gene WT1 product. J Immunol 2000 164 : 1873.
44. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003 78 : 56.
45. Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004 48 : 175.